Clinical Ophthalmology (Dec 2021)
Characteristics and Outcomes of a Series of COVID-Associated Mucormycosis Patients in Two Different Settings in Egypt Through the Third Pandemic Wave
Abstract
Yousef A Fouad,1,2 Hatem M Bakre,3 Mahmoud A Nassar,4 Mohamed Omar A Gad,5 Ashraf Abdelsalam Kandeel Shaat1,2 1Department of Ophthalmology, Ain Shams University Hospitals, Cairo, Egypt; 2Oculoplastic Service, Al Mashreq Eye Center, Cairo, Egypt; 3Faculty of Medicine, Aswan University, Aswan, Egypt; 4Faculty of Medicine, Assuit University, Assuit, Egypt; 5ENT Department, Assuit University Hospitals, Assuit, EgyptCorrespondence: Yousef A FouadOphthalmology Department, Ain Shams University, Ramses Street, Abbassiya, Cairo, 11517, EgyptTel +201063781237Email [email protected]: To report on the underlying risk factors, clinical characteristics, presentation, and survival of coronavirus disease 2019 (COVID-19) associated mucormycosis (CAM) cases referred for ophthalmological consultation in two different Egyptian settings during the third viral pandemic wave (April to August of 2021).Methods: A multicentric, retrospective analysis involving one public and two private hospitals in metropolitan Cairo, and two university hospitals in upper Egypt (Aswan and Assuit). Cases that fulfilled the diagnostic criteria of mucormycosis, with a prior or concurrent COVID-19 infection, were included.Results: Of the 26 patients included in the final analysis, 15 (57.7%) were from Cairo and 11 (42.3%) were from upper Egypt. Twenty-five patients (96.2%) had poorly controlled diabetes mellitus and 20 (76.9%) had received corticosteroid treatment for COVID-19, of which 30.8% had mild or moderate disease. The median duration from COVID-19 till the onset of CAM was 20.5 days. No visual function could be detected in the affected eye of 16 patients (61.6%) on presentation. The mortality rate was 46.2% despite surgical debridement in half of the cases that died.Conclusion: CAM continues to be a concrete threat throughout Egypt, especially in patients with poorly controlled diabetes mellitus and those who inadvertently receive steroid therapy. It remains to be seen if increased vaccination coverage and early detection due to increased awareness would result in declining rates and adverse sequelae of CAM. A national registry would allow for better monitoring of the disease trends.Keywords: coronavirus disease 2019, COVID-19, mucormycosis, COVID-associated mucormycosis, invasive fungal sinusitis
